Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.

Introduction: In the OPTIMISMM trial, pomalidomide/bortezomib/dexamethasone (PVd) significantly prolonged median progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) in lenalidomide-exposed relapsed and refractory multiple myeloma (RRMM). We report final overall survival (OS) and updated efficacy analyses.

Methods: Adults with RRMM who had 1-3 prior regimens, including lenalidomide (≥ 2 cycles), were assigned (1:1) to PVd or Vd.

Optimization of Laser-Wavelength Dependence for Open-Air Atmospheric Pressure Pulsed Laser Deposition of AlCrFeMnTi High-Entropy Alloy for Tailored Surface Properties.

High-entropy alloys (HEAs) have garnered significant attention in different fields due to their exceptional mechanical and physical properties, making them promising candidates for various applications. Several techniques, including physical vapor deposition and pulsed laser deposition (PLD), have been employed for the fabrication of HEA thin films. In this study, we explore a novel approach to synthesizing the lightweight HEA (LWHEA) AlCrFeMnTi using PLD in air at atmospheric pressure with a particular focus on the influence of the laser wavelength on the deposition process and the resulting alloy characteristics.

ALD-Engineered CuO Overlayers Transform ZnO Nanorods for Selective Production of CO in Electrochemical CO Reduction.

The electrochemical CO reduction reaction (CORR) holds tremendous promise as a strategy for lowering atmospheric CO levels and creating new clean energy sources. The conversion of CORR to CO, in particular, has garnered significant scientific interest due to its industrial feasibility. Within this context, the CuZn-based electrocatalyst presents an attractive alternative to conventional CO-selective electrocatalysts, which are often costly and scarce.

Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment.

Introduction: A proportion of patients with multiple myeloma (MM) are older and/or have comorbidities, requiring dose adjustments. Data from OPTIMISMM (NCT01734928) supported the use of pomalidomide, bortezomib, and dexamethasone (PVd) for treating relapsed/refractory MM. This subanalysis of OPTIMISMM assessed outcome by frailty and/or bortezomib dose adjustment.